Bullous pemphigoid (BP) is the most frequent autoimmune skin disease and mainly affects elderly individuals. BP classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense itches. However, BP is characterized by a large spectrum of clinical presentations allowing to distinguish between typical (with blisters) and atypical forms (non bullous, mucosal damage). High potency topical steroids and systemic steroids are the current first line intention treatments. While very efficient, these therapies are non-targeted and cause numerous side-effects, especially in these elderly patients that are the most affected. Furthermore, around 30% of BP patients will relapse during the first year of treatment when corticotherapy is decreased or stopped. The investigators and others have highlighted the presence of Il-17 family belonging-inflammatory cytokines in BP patients. Their functions in the amplification of the inflammatory response and in the mechanisms of relapse have to be precisely determined in order to develop innovative therapeutic approaches and to move forwards precision medicine.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Identification of IL-17RB-expressing cells and IL-17B-producing cells in blood
Timeframe: Day 1
Identification of IL-17RB-expressing cells and IL-17B-producing cells in blood
Timeframe: Day 30
Identification of IL-17RB-expressing cells and IL-17B-producing cells in blood
Timeframe: Day 60
Identification of IL-17RB-expressing cells and IL-17B-producing cells in blood
Timeframe: Day 90
Identification of IL-17RB-expressing cells and IL-17B-producing cells in blood
Timeframe: Day 150
Identification of IL-17RB-expressing cells and IL-17B-producing cells in blood
Timeframe: Day 270
Identification of IL-17RB-expressing cells and IL-17B-producing cells in blood
Timeframe: Day 365
Identification of IL-17RB-expressing cells at the lesional site
Timeframe: Day 1
Identification of IL-17RB-expressing cells at the lesional site
Timeframe: Day 60